respiratory
Cystic fibrosis

CF drug knocked back for the third time


The Pharmaceutical Benefits Advisory Committee has rejected, for the third time, an application to have the potentially life saving cystic fibrosis treatment Orkambi listed on the Pharmaceutical Benefits Scheme (PBS). The drug’s manufacturer, Vertex, is seeking an Authority Required listing for the combination drug (lumacaftor 200mg and ivacaftor 125mg) to treat patients with cystic fibrosis ...

Already a member?

Enter your email to keep reading.


OR